Targeted Radiowave Advantage Micrima’s Mi~Scan and Mi~Score combine radio frequency tissue analysis with AI-driven risk assessment, enabling a differentiated offering for early breast cancer detection that can be pitched to clinics seeking innovative imaging modalities and personalized risk stratification.

Clinical Adoption Path With active involvement in RSNA history and a clear goal of frequent breast imaging to reduce mortality, position conversations around integration into routine screening workflows, training for clinicians, and evidence generation to accelerate clinical adoption.

Regulatory and Standards Fit Mi~Scan produces BI-RADS density classifications and integrates with established risk models, aligning with standard breast imaging practices; leverage this compatibility to reassure hospital procurement teams and radiology consultants about interoperability and compliance.

Growth and Funding Signals Historical funding rounds and ongoing product development indicate a traction-focused growth phase; target investors, grant programs, and strategic partners in medical imaging to accelerate commercialization and expand regional presence.

Market Positioning As a Bristol-based medical device with a small but focused team, emphasize cost-effective, scalable imaging technology for wider age groups and diverse populations, appealing to mid-sized radiology centers and early adopters seeking competitive differentiation.